William Rice

Outlook Amazon AWS Apache Mobile Friendly reCAPTCHA Google Tag Manager Google Analytics Remote

oncology myelodysplastic syndromes acute myeloid leukemia hematology drug development discovery chronic lymphocytic leukemia non hodgkins lymphoma biotechnology: biological products (no diagnostic substances) health care biotechnology research precision oncology clinical-stage biotechnology oncology therapies hematologic malignancies small molecule therapeutics single agent efficacy drug candidates oral kinase inhibitors tuspetinib luxeptinib flt3 inhibitor btk inhibitor myeloid malignancies b-cell malignancies relapsed aml refractory aml clinical trials aml treatment expanded access nhl treatment cll treatment safety profile therapeutic potential cancer patients combinational therapy mutationally diverse populations pk analysis standard of care investigational drug candidates clinical efficacy drug target validation regulatory affairs biopharmaceutical development patient outcomes mutation-agnostic therapy oncogenic pathways kinome inhibitors non-overlapping toxicities biotechnology innovation cancer research quality of life novel cancer therapies leadership in oncology collaborative research translational medicine investor relations biotech investments financial performance research & development hospital & health care health wellness & fitness